Protagonist Therapeutics, Inc. has grown revenue 20% a year over three years and 60% a year over five. Revenue growth, 3-year annual rate: +20% (Biotechnology median +17%). Revenue growth, 5-year rate: +60%, growth has slowed since the five-year average. Years of annual history on file: 12, FY2014 to FY2025, as filed.

PTGXProtagonist Therapeutics, Inc.

Healthcare

$143.75+131% 1Y

$143.75

$64.0052 weeks$158.64

Is it growing?

Excellent

Growing: revenue growing +35% year on year, earnings up +40% year on year, and operating margin widening (+11.1 points).

3 good

Revenue trend+35% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +60% a year.

Earnings trend+40% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing faster than revenue, so margins or the share count are helping.

Margin direction+11.1 points operating

Trailing-twelve-month operating margin, -398.6% now against -409.7% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is PTGX growing?

Protagonist Therapeutics, Inc. has grown revenue 20% a year over three years and 60% a year over five.

+20%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from fiscal-year columns as filed

Revenue growth, 5-year rate: +60%
Revenue growth, 5-year rate · +20% over three · growth has slowed since the five-year average
Years of annual history on file: 12
Years of annual history on file · FY2014 to FY2025, as filed

Details›